SIOX NASDAQ
Sio Gene Therapies Inc.
1W: +22.9%
1M: +22.9%
3M: +21.0%
1Y: +4.9%
3Y: -83.5%
5Y: -94.9%
$0.48
Last traded 2024-02-07 — delisted
Overview
News
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Dividends
Analysis
Technicals
Weather
Peers
ESG
Institutions
Dark Pool
Short Interest
Income Trends
Revenue
$0
+0.0% ▲
Gross Profit
$0
+0.0% ▲
Operating Income
-$72M
-110.7% ▼
Net Income
-$72M
-121.7% ▼
EPS (Diluted)
$-0.98
-58.1% ▼
EBITDA
-$71M
-141.5% ▼
Profit Margins
Year-over-Year Growth
View Full Income Statement
| Line Item | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 |
|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 | $0 |
| YoY Growth | +0.0% | +0.0% | +0.0% | +0.0% | +0.0% |
| Cost of Revenue | $0 | $0 | $0 | $0 | $0 |
| Gross Profit | $0 | $0 | $0 | $0 | $0 |
| Gross Margin | — | — | — | — | — |
| R&D Expenses | $141M | $88M | $47M | $25M | $53M |
| SG&A Expenses | $72M | $39M | $22M | $17M | $18M |
| Operating Expenses | $213M | $127M | $69M | $42M | $72M |
| Operating Income | -$213M | -$127M | -$68M | -$34M | -$72M |
| Operating Margin | — | — | — | — | — |
| Interest Expense | $8M | $8M | $4M | $799K | $27K |
| Income Before Tax | -$221M | -$129M | -$72M | -$33M | -$72M |
| Tax Expense | $921K | $133K | $438K | -$212K | $259K |
| Net Income | -$222M | -$129M | -$73M | -$32M | -$72M |
| Net Margin | — | — | — | — | — |
| EPS (Diluted) | $-16.51 | $-8.02 | $-2.93 | $-0.62 | $-0.98 |
| EBITDA | -$210M | -$119M | $0 | -$29M | -$71M |
| Shares Outstanding | 13M | 16M | 25M | 52M | 73M |